Search
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalAlaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.
Penimepicycline
go.drugbank.com/drugs/DB13264ExperimentalIt is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
Triazolam
go.drugbank.com/drugs/DB00897ApprovedInvestigationalWithdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Rubidium Rb-82
go.drugbank.com/drugs/DB09479ApprovedInvestigationalRubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate ...
GRAd-COV2
go.drugbank.com/drugs/DB16428InvestigationalGRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].
BB-301
go.drugbank.com/drugs/DB17011Investigational[A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.
Enlonstobart
go.drugbank.com/drugs/DB21890Investigational[A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.
Cilobradine
go.drugbank.com/drugs/DB20039InvestigationalCilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).